Theriva Biologics (TOVX) Goodwill & Intangibles (2010 - 2026)

Theriva Biologics (TOVX) has reported Goodwill & Intangibles for 7 consecutive years, with $19.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill & Intangibles rose 6.31% year-over-year to $19.2 million; the TTM figure through Mar 2026 stood at $19.2 million (up 6.31% YoY), while the FY2025 annual figure was $19.6 million, up 13.03% from the prior year.
• Goodwill & Intangibles slipped to $19.2 million in Q1 2026 per TOVX's latest filing, from $19.6 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $27.7 million in Q1 2022 and bottomed at $17.4 million in Q4 2024.
• Historically, Goodwill & Intangibles has averaged $22.3 million across 5 years, with a median of $22.8 million in 2022.
• Annual changes were most pronounced in 2023 — Goodwill & Intangibles gained 28.84% — and 2024, when it sank 31.81%.
• Theriva Biologics' Goodwill & Intangibles stood at $19.8 million in 2022, then climbed by 28.84% to $25.5 million in 2023, then tumbled by 31.81% to $17.4 million in 2024, then grew by 13.03% to $19.6 million in 2025, then decreased by 2.01% to $19.2 million in 2026.
• Business Quant data shows TOVX's Goodwill & Intangibles at $19.2 million in Q1 2026, $19.6 million in Q4 2025, and $19.6 million in Q3 2025.